Regulatory Authority Empowered to Reject Future Applications of Dishonest Firms

NEW DELHI, Aug 6 — The Union Health Ministry has upgraded the powers of drug licensing bodies through an amendment to the Drug Rules, 1945, announced via Gazette No. 756 (E) on 16 October 2025. The added provision allows regulators to block any subsequent licence applications from entities that have previously furnished false or fabricated data in support of their submissions.

The rule applies uniformly across all types of applications under the 1945 framework. While earlier enforcement could only invalidate a current request or cancel an active licence, the new clause imposes a statutory moratorium on future filings for a defined period, after serving a notice of cause and granting an appeal route.

The move is aimed at reinforcing the credibility of scientific evidence used to evaluate drug safety, efficacy, and quality. By penalising dishonest conduct, the ministry seeks to align India’s drug oversight with international standards, promote compliance among manufacturers, and protect the population from health hazards associated with falsified information.